BML Capital Management LLC Buys New Holdings in Talis Biomedical Co. (NASDAQ:TLIS)

BML Capital Management LLC bought a new stake in shares of Talis Biomedical Co. (NASDAQ:TLIS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 42,743 shares of the company’s stock, valued at approximately $318,000. BML Capital Management LLC owned 2.35% of Talis Biomedical at the end of the most recent quarter.

Separately, Citigroup Inc. bought a new stake in Talis Biomedical during the 3rd quarter valued at approximately $30,000. Institutional investors own 43.77% of the company’s stock.

Talis Biomedical Price Performance

Shares of TLIS opened at $9.05 on Wednesday. The business’s 50 day moving average is $8.57 and its 200 day moving average is $7.59. Talis Biomedical Co. has a 12-month low of $4.35 and a 12-month high of $9.32.

Talis Biomedical (NASDAQ:TLIS) last released its quarterly earnings results on Thursday, March 28th. The company reported ($7.39) earnings per share for the quarter. The firm had revenue of $0.20 million for the quarter. Talis Biomedical had a negative net margin of 2,905.67% and a negative return on equity of 69.49%.

Talis Biomedical Profile

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B.